Acetaminophen resolution
This article was originally published in The Tan Sheet
Executive Summary
Group also resolves to support legislation to "require, on a national level, enhanced package warning labels on acetaminophen-containing products warning patients that liver failure can result from taking the product in combination with even moderate amounts of alcohol or from taking the product in dosages greater than advised in instructions." AMA also reiterated its call to ban sale of ephedra supplements in the U.S. (1"The Tan Sheet" Feb. 18, 2002, In Brief)...
You may also be interested in...
Maves’ change of heart on ephedra
Letter to FDA signed by former CHPA President and current American Medical Association Exec VP & CEO Michael Maves, MD, reiterates AMA's call for ephedrine alkaloid products to be removed from the market due to the number of related AERs. While Maves was at CHPA, the trade association opposed FDA's reliance on AERs in developing regulatory restrictions for ephedrine alkaloid products. However, in a Jan. 28 letter, Maves states "the number of AERs associated with dietary supplements containing ephedrine alkaloids is alarming"...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.